200 related articles for article (PubMed ID: 34720085)
1. Dual role of allele-specific DNA hypermethylation within the TERT promoter in cancer.
Lee DD; Komosa M; Sudhaman S; Leão R; Zhang CH; Apolonio JD; Hermanns T; Wild PJ; Klocker H; Nassiri F; Zadeh G; Diplas BH; Yan H; Gallinger S; Pugh TJ; Ramaswamy V; Taylor MD; Castelo-Branco P; Nunes NM; Tabori U
J Clin Invest; 2021 Nov; 131(21):. PubMed ID: 34720085
[TBL] [Abstract][Full Text] [Related]
2. DNA hypermethylation within TERT promoter upregulates TERT expression in cancer.
Lee DD; Leão R; Komosa M; Gallo M; Zhang CH; Lipman T; Remke M; Heidari A; Nunes NM; Apolónio JD; Price AJ; De Mello RA; Dias JS; Huntsman D; Hermanns T; Wild PJ; Vanner R; Zadeh G; Karamchandani J; Das S; Taylor MD; Hawkins CE; Wasserman JD; Figueiredo A; Hamilton RJ; Minden MD; Wani K; Diplas B; Yan H; Aldape K; Akbari MR; Danesh A; Pugh TJ; Dirks PB; Castelo-Branco P; Tabori U
J Clin Invest; 2019 Jan; 129(1):223-229. PubMed ID: 30358567
[TBL] [Abstract][Full Text] [Related]
3. Allele-specific proximal promoter hypomethylation of the telomerase reverse transcriptase gene (TERT) associates with TERT expression in multiple cancers.
Rowland TJ; Bonham AJ; Cech TR
Mol Oncol; 2020 Oct; 14(10):2358-2374. PubMed ID: 33245585
[TBL] [Abstract][Full Text] [Related]
4. Pervasive promoter hypermethylation of silenced TERT alleles in human cancers.
Esopi D; Graham MK; Brosnan-Cashman JA; Meyers J; Vaghasia A; Gupta A; Kumar B; Haffner MC; Heaphy CM; De Marzo AM; Meeker AK; Nelson WG; Wheelan SJ; Yegnasubramanian S
Cell Oncol (Dordr); 2020 Oct; 43(5):847-861. PubMed ID: 32468444
[TBL] [Abstract][Full Text] [Related]
5. Combined genetic and epigenetic alterations of the TERT promoter affect clinical and biological behavior of bladder cancer.
Leão R; Lee D; Figueiredo A; Hermanns T; Wild P; Komosa M; Lau I; Mistry M; Nunes NM; Price AJ; Zhang C; Lipman T; Poyet C; Valtcheva N; Oehl K; Coelho H; Sayyid R; Gomes AM; Prado E Castro L; Sweet J; Vinagre J; Apolónio J; Stephens D; Faleiro I; Fadaak K; Richard PO; Kulkarni G; Zlotta AR; Hamilton RJ; Castelo-Branco P; Tabori U
Int J Cancer; 2019 Apr; 144(7):1676-1684. PubMed ID: 30350309
[TBL] [Abstract][Full Text] [Related]
6. A cancer specific hypermethylation signature of the TERT promoter predicts biochemical relapse in prostate cancer: a retrospective cohort study.
Castelo-Branco P; Leão R; Lipman T; Campbell B; Lee D; Price A; Zhang C; Heidari A; Stephens D; Boerno S; Coelho H; Gomes A; Domingos C; Apolonio JD; Schäfer G; Bristow RG; Schweiger MR; Hamilton R; Zlotta A; Figueiredo A; Klocker H; Sültmann H; Tabori U
Oncotarget; 2016 Sep; 7(36):57726-57736. PubMed ID: 27437772
[TBL] [Abstract][Full Text] [Related]
7. Methylation of the TERT promoter and risk stratification of childhood brain tumours: an integrative genomic and molecular study.
Castelo-Branco P; Choufani S; Mack S; Gallagher D; Zhang C; Lipman T; Zhukova N; Walker EJ; Martin D; Merino D; Wasserman JD; Elizabeth C; Alon N; Zhang L; Hovestadt V; Kool M; Jones DT; Zadeh G; Croul S; Hawkins C; Hitzler J; Wang JC; Baruchel S; Dirks PB; Malkin D; Pfister S; Taylor MD; Weksberg R; Tabori U
Lancet Oncol; 2013 May; 14(6):534-42. PubMed ID: 23598174
[TBL] [Abstract][Full Text] [Related]
8. The TERT hypermethylated oncologic region predicts recurrence and survival in pancreatic cancer.
Faleiro I; Apolónio JD; Price AJ; De Mello RA; Roberto VP; Tabori U; Castelo-Branco P
Future Oncol; 2017 Oct; 13(23):2045-2051. PubMed ID: 29019414
[TBL] [Abstract][Full Text] [Related]
9. Characterization of human telomerase reverse transcriptase promoter methylation and transcription factor binding in differentiated thyroid cancer cell lines.
Avin BA; Wang Y; Gilpatrick T; Workman RE; Lee I; Timp W; Umbricht CB; Zeiger MA
Genes Chromosomes Cancer; 2019 Aug; 58(8):530-540. PubMed ID: 30664813
[TBL] [Abstract][Full Text] [Related]
10. Characterization of Allele-Specific Regulation of Telomerase Reverse Transcriptase in Promoter Mutant Thyroid Cancer Cell Lines.
McKelvey BA; Gilpatrick T; Wang Y; Timp W; Umbricht CB; Zeiger MA
Thyroid; 2020 Oct; 30(10):1470-1481. PubMed ID: 32228178
[No Abstract] [Full Text] [Related]
11. DNA methylation of the TERT promoter and its impact on human cancer.
Lee DD; Komosa M; Nunes NM; Tabori U
Curr Opin Genet Dev; 2020 Feb; 60():17-24. PubMed ID: 32114294
[TBL] [Abstract][Full Text] [Related]
12.
Liu L; Liu C; Fotouhi O; Fan Y; Wang K; Xia C; Shi B; Zhang G; Wang K; Kong F; Larsson C; Hu S; Xu D
Oncologist; 2017 Oct; 22(10):1178-1188. PubMed ID: 28754720
[TBL] [Abstract][Full Text] [Related]
13. Targeting oncogenic TERT promoter variants by allele-specific epigenome editing.
Kouroukli AG; Rajaram N; Bashtrykov P; Kretzmer H; Siebert R; Jeltsch A; Bens S
Clin Epigenetics; 2023 Nov; 15(1):183. PubMed ID: 37993930
[TBL] [Abstract][Full Text] [Related]
14. Allele-Specific DNA Methylation and Its Interplay with Repressive Histone Marks at Promoter-Mutant TERT Genes.
Stern JL; Paucek RD; Huang FW; Ghandi M; Nwumeh R; Costello JC; Cech TR
Cell Rep; 2017 Dec; 21(13):3700-3707. PubMed ID: 29281820
[TBL] [Abstract][Full Text] [Related]
15. Exploring the epigenetic regulation of telomerase reverse transcriptase (TERT) in human cancer cell lines.
McKelvey BA; Zeiger MA; Umbricht CB
Mol Oncol; 2020 Oct; 14(10):2355-2357. PubMed ID: 32920953
[TBL] [Abstract][Full Text] [Related]
16. Telomerase activation in small intestinal neuroendocrine tumours is associated with aberrant
Fotouhi O; Ghaderi M; Wang N; Zedenius J; Kjellman M; Xu D; Juhlin CC; Larsson C
Epigenetics; 2019 Dec; 14(12):1224-1233. PubMed ID: 31322481
[TBL] [Abstract][Full Text] [Related]
17. TERT promoter mutations and telomeres during tumorigenesis.
Lorbeer FK; Hockemeyer D
Curr Opin Genet Dev; 2020 Feb; 60():56-62. PubMed ID: 32163830
[TBL] [Abstract][Full Text] [Related]
18. THOR is a targetable epigenetic biomarker with clinical implications in breast cancer.
Apolónio JD; Dias JS; Fernandes MT; Komosa M; Lipman T; Zhang CH; Leão R; Lee D; Nunes NM; Maia AT; Morera JL; Vicioso L; Tabori U; Castelo-Branco P
Clin Epigenetics; 2022 Dec; 14(1):178. PubMed ID: 36529814
[TBL] [Abstract][Full Text] [Related]
19. A Pan-Cancer Study of Somatic TERT Promoter Mutations and Amplification in 30,773 Tumors Profiled by Clinical Genomic Sequencing.
Gupta S; Vanderbilt CM; Lin YT; Benhamida JK; Jungbluth AA; Rana S; Momeni-Boroujeni A; Chang JC; Mcfarlane T; Salazar P; Mullaney K; Middha S; Zehir A; Gopalan A; Bale TA; Ganly I; Arcila ME; Benayed R; Berger MF; Ladanyi M; Dogan S
J Mol Diagn; 2021 Feb; 23(2):253-263. PubMed ID: 33285287
[TBL] [Abstract][Full Text] [Related]
20. Telomerase reverse transcriptase promoter alterations across cancer types as detected by next-generation sequencing: A clinical and molecular analysis of 423 patients.
Schwaederle M; Krishnamurthy N; Daniels GA; Piccioni DE; Kesari S; Fanta PT; Schwab RB; Patel SP; Parker BA; Kurzrock R
Cancer; 2018 Mar; 124(6):1288-1296. PubMed ID: 29211306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
